| Objective：Chronic gastritis (CG) refers to chronic inflammatory lesions gastric mucosawhich caused by various pathogenesis.The pathogenesis related to H.pylori infection, bileregurgitation, smoking, drinking, taking NSAID drugs, mental factors and stress,etc. Themain performance is: the repeated epigastric pain, early satiety, nausea, vomiting, loss ofappetite, belching, etc. Deanxit (H. Lundbeck A/S production, product name: Deanxit,the following abbreviations) is a kind of antidepressant dedication, can improve theinternal tolerance and reduce the sensitivity. This research mainly discusses clinicaleffectiveness and safety with conventional treatment and taking Deanxit therapy inpatients with CG, who have anxiety and depression, in order to further study thepathogenesis of CG and provide theoretical foundation treatment.Methods：With90patients randomly divided into towo groups.Treatment group: to takeDeanxit after breakfast and lunch two times a day, each time a piece of10.5mg, eightweeks treatment meanwhile take inhibitory acid drug and/or promote gastrointestinalmedicine, Omeprazole(20mg2times/day) and/or Mosapride (5mg3times/day).Controlgroup: use acid-inhibitory drugs and/or promote gastrointestinal medicine, Omeprazole(20mg2times/day) and/or Mosapride (5mg3times/day) and may choose gastricmucosa protectant. Have electrolyte biochemical inspection before and after test such ashematuria dung routine, liver and kidney function, etc. Meanwhile, gastroscope,B-ultrasonic wave, electrocardiogram. To observe gastrointestinal symptoms score, HAMA and HAMD scores at0,1st,2nd,4th,8th week. To record the QLQ, PSQI, WLTat0,8th week. To record adverse event on patients during treatment. Using t test formeasurement data, the results are showed by mean±standard deviation, X±S and P<0.05for a significant difference.Results：1.Gastrointestinal symptoms scores in the test group before treatment and after eightweeks treatment, HAMA and HAMD, QLQ, PSQI, difference of WLT have statisticalsignificance. Gastrointestinal score before treatment,24.77±10.55, is significantly higherthan eight weeks’ score,6.06±2.50,P<0.05. Before treatment with HAMA25.77±6.06which is significantly higher than the number from the treatment later,9.08±3.40，P <0.05. The number of HAMD before treatment is35.97±9.94,which is significantlyhigher than that after treatment,11.51±3.79,P<0.05. Before treatment, water load is912.40±260.02ml,that is obviously lower than1149.11±270.42ml， P<0.05. Beforetreatment,QLQ score stays with91.84±9.52,which is significantly lower than that later,102.33±9.55，P<0.05. PSQI score before treatment is significantly higher than that aftertreatment,12.48±2.87vs.7.57±2.31,P<0.05.2.In control group,the gastrointestinal symptoms score before treatment and aftereight weeks’ treatment, the difference of HAMA and HAMD score have statisticalsignificance, meanwhile, the difference for water capacity has no statistically significant.Before treatment with25.48±10.96, gastrointestinal symptoms score is significantlyhigher than later,11.55±6.63,P<0.05. Before treatment with HAMA scored26.51±6.10,is significantly higher than11.48±4.33,P<0.05. The number of HAMD beforetreatment with36.46±9.93is significantly higher than that after treatment, which scored11.48±4.33,P<0.05. Before treatment, QLQ is91.46±10.03,after treatment the numberbecomes a low value,97.60±10.27,P<0.05. Before treatment, PSQI is significantlyhigher than that values after treatment with12.46±2.93vs.10.11±2.58，P<0.05. Beforetreatment, WLT stays with907.00±255.73ml,after treatment, the water capacity changesinto908.00±255.01ml,P>0.05, the difference was not statistically significant. 3. After doing treatments for eight weeks,the test group and the control group withthe differences in the aspects of HAMA, HAMD, gastrointestinal symptoms score andquality of life, QLQ, WLThave statistical significance. After treatment, thegastrointestinal score in test group,6.06±2.50,is significantly lower than that in controlgroup,11.55±6.63，P <0.05. After treatment, the HAMA score in test group,9.08±3.40,becomes significantly lower than that in control group,11.48±4.33, P <0.05. Aftertreatment, the test group’s HAMD scores differed significantly lower than those of thecontrol group,11.51±3.79vs.18.93±8.08,P<0.05. After treatment, the water load intreatment group,1149.11±270.42ml, is significantly higher than those in the controlgroup908.00±255.01ml,P<0.05. The test group’s QLQ scored102.33±9.55,which issignificantly higher than that in the control group,97.60±10.27,P <0.05. After treatment,the number of QLQ in test group stays with7.57±2.31,that is significantly lower than thatin control group,10.11±2.58,P <0.05.Conclusion：1.Acid inhibitors and gastrointestinal motility promoting medicines are effective on treating CG and alleviating gastroenterological symptoms.And the effect can be more apparent to CG patients with anxiety depression when combined with Deanxit.(improve gastrointestinal symptoms, decrease HAMA, HAMD and quality of sleep, increase the life quality score a-nd water load.)2. Gastrointestinal symptoms score, HAMA and HAMD are accurate indicator forCG patients with anxiety, depression.3. In the two groups CG patients with anxiety depression which found that waterload increase significantly, difference have statistical significance.4.In the methods of detecting capacity of the stomach bottom function, WLT issimple, noninvasive, safe, inexpensive, which accords with gastrointestinal physiology.5. Deanxit has exactly curative effect, little adverse reaction and good tolerance formental symptoms of chronic gastritis patients. |
PDF Full Text Request